Apricot Capital is a venture capital firm founded in 2015 and based in Shanghai, China, deeply rooted in China's healthcare ecosystem. The firm specializes in incubating and scaling early- and growth-stage companies in biotech, medtech, and life sciences to address unmet global clinical needs.
Deal activity increased 300% year-over-year (4 deals in the last 12 months). Average disclosed round size is $71.1M (across 9 rounds with reported amounts).
Portfolio
11
Fund Size
—
Top Stage
Series A
Last 12 Mo
5
Team
Arthur Qiang
Managing Partner Ph. D. CFA FRM
Crystal Liu
Managing Partner Dr. PH
William Mao
Managing Partner MS / EMBA
Haigang Chen
Partner M. D
Wei Ding
Partner Ph.D.
Yakun Ding
Partner MS
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Vvivacta biotechnology | Series A | $50M | Apr 2026 |
| VVivaTides Therapeutics | Series A | $54M | Apr 2026 |
| VVivaTides Therapeutics | Seed | — | Apr 2026 |
 Vibrant Therapeutics | Series C | $61M | Jan 2026 |
 QL Biopharm | Unknown | $200M | Jan 2026 |
| QQi Biodesign | Series A | $75M | Dec 2024 |
| MMediLink | Series A | — | Mar 2021 |
| SShengsheng | Series C | — | Jan 2021 |
| AAmbrx Inc | Unknown | $45M | Nov 2020 |
| SShengsheng | Series B | — | Jan 2020 |
| SShengsheng | Series A | — | Jan 2018 |
| SShengsheng | Seed | — | Jan 2017 |
| GGolden Duck | Unknown | — | — |
| BBellen Chemistry | Unknown | $30M | — |
| VVivacta | Series A | $50M | — |
| QQi Biodesign | Seed | $75M | — |
Top Co-Investors
Loyal Valley Capital3 shared
OrbiMed3 shared
Hankang Capital2 shared
Decheng Capital2 shared
C&D Emerging Industry Equity Investment2 shared
TSG Consumer Partners1 shared
Northern Light Venture Capital1 shared
Badlands Capital1 shared
Pfizer Ventures1 shared
HongShan1 shared
5Y Capital1 shared
Legend Star1 shared
Maverick Ventures1 shared
Adage Capital Management1 shared
Suvretta Capital1 shared
Hopu Investments1 shared
The Invus Group, LLC1 shared
HBM Healthcare Investments1 shared
Versant Ventures1 shared
Last updated: 8 September 2026